Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
about
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancerTaxane pathway.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceCytochrome P450 2C8 pharmacogenetics: a review of clinical studiesThe role of genetic variability in drug metabolism pathways in breast cancer prognosis.The role of drug-metabolising enzymes in clinical responses to chemotherapy.Pharmacogenetics and oncology treatment for breast cancer.Pharmaco(epi)genomics in ovarian cancer.Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.Level of evidence for therapeutic drug monitoring of taxanes.Germline pharmacogenetics of paclitaxel for cancer treatment.Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.Rapid and sensitive liquid chromatographic method for determination of Paclitaxel from parenteral formulation and nanoparticlesPotential drug interaction between paclitaxel and clopidogrel.Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel.Pharmacogenomics of importance for paclitaxel chemotherapy.Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic.Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
P2860
Q27851688-1DBA8BF0-7020-4E0A-B324-913722BAADDDQ33422082-5C4B64C0-F5F7-454D-BA60-75173E5B92DCQ34390370-BCA12C7F-A3A1-4555-AEC0-69B476CCC1F5Q34774854-741E0F04-BB0E-4C4F-89F2-4D54EA93C439Q35003605-D8811B93-80C8-4FF1-ADA8-91DFE8E9A3F1Q36497088-483DA55F-A73D-4154-B233-F720C863A401Q36545015-EF9D0A2C-9057-4D09-994C-5002316AD677Q36719659-92AC6D3B-85CD-402F-A50F-0A17CAAC8191Q37346198-5037B556-74D4-40F1-BE8C-9B0E606B4554Q37684533-E0E6D68D-5AB1-42E3-8AED-51ED89534722Q37725978-E09A5984-5EFF-4716-85D3-26AD95384586Q37788732-6A91C9E7-A8BB-4898-AF49-3A69A06680F4Q38120289-E95C7B91-67B2-44E2-987B-2F773B0CE021Q38222511-4D9E5100-24A1-4069-AE8A-639A2D7FD977Q38414396-73E9D913-AB56-48E7-B623-E81986AC4D70Q39702921-85C78D6F-3451-446F-B3CE-A8BC183314E4Q40732067-67FFD73A-970E-4340-980B-28D2F09723CAQ41577007-EE2AE10D-DD82-4471-B1C5-205A878DDEBBQ42177423-D197C46F-39E2-4DC1-868B-E31FBE959E83Q43025585-2C50B290-5711-435B-B044-AFD6F250FC79Q46563276-DD8E10A5-82F6-4EB9-BCC5-006574DC1D31Q47211627-E021B41F-A927-4D4B-8C49-F96CFFEC54A0Q47376469-FE58116C-DABC-4AC7-9C45-E22BF4F3FFCBQ50526560-ED576928-2A0E-48D1-9A5F-AD9A2BEB8AE9
P2860
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacokinetics of paclitaxel ...... s of CYP2C8, CYP3A4, and MDR1.
@ast
Pharmacokinetics of paclitaxel ...... s of CYP2C8, CYP3A4, and MDR1.
@en
type
label
Pharmacokinetics of paclitaxel ...... s of CYP2C8, CYP3A4, and MDR1.
@ast
Pharmacokinetics of paclitaxel ...... s of CYP2C8, CYP3A4, and MDR1.
@en
prefLabel
Pharmacokinetics of paclitaxel ...... s of CYP2C8, CYP3A4, and MDR1.
@ast
Pharmacokinetics of paclitaxel ...... s of CYP2C8, CYP3A4, and MDR1.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of paclitaxel ...... s of CYP2C8, CYP3A4, and MDR1.
@en
P2093
Masaaki Tanaka
Masaki Inoue
Miki Nakajima
Mitsuhiro Nakamura
Satoru Kyo
Taro Kanaya
Tsuyoshi Yokoi
Yoshiko Maida
Yuto Fujiki
P2860
P304
P356
10.1177/0091270005276204
P577
2005-06-01T00:00:00Z